CXCR4 inhibitors have been shown to significantly improve the TME in pancreatic cancer and increase the sensitivity of tumors to immune checkpoint inhibitors, increasing the benefits of immunotherapy in pancreatic cancer [20]. This evidence concerns the gene CXCR4 and familial pancreatic carcinoma.